In a clinical trial involving 1,169 people with relapsing-remitting MS, oral teriflunomide (Genzyme/Sanofi-Aventis) reduced relapses compared with placebo according to a recent company press release. An application for marketing approval of teriflunomide was accepted for review by the FDA in October.

Everyday Matters will highlight five inspiring stories of people affected by MS, each focused on something that we all strive to enhance every day. Join the journey for resources and ideas — first by voting on the topic that most impacts your everyday life. Everyday Matters is supported by Genzyme.

Join us Monday, June 18, 2012 at 4:00 pm ET for a live community chat focusing on progressive MS. Society Chief Research Officer, Tim Coetzee, and Peter Calabresi, MD, will be live in the MS Connection community.

MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS. JOIN THE MOVEMENT®

Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — pleasevisit our website.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.